Xeris Pharmaceuticals XERS 深 沪
等待开盘 09-16 09:30:00 美东时间
7.49
-0.080
-1.06%
华盛通- 最 高7.58
- 今 开7.57
- 成交量 118.10万股
- 最 低 7.41
- 昨 收 7.57
- 总市值 13.66亿
- 52周最高 10.08
- 市盈率 静 2340.63
- 换手率 0.65%
- 52周最低 5.25
- 委 比 -76.08%
- 总股本 1.82亿
- 历史最高 27.983
- 量 比 0.56
- 振 幅 2.25%
- 历史最低 0.9701
- 每 手 1
- 风险率 1.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
Xeris Biopharma To Host XP‑8121 Program Overview Detailing Phase 3 Study And Commercial Opportunity; Topline Results Expected In Late 2028; FDA Approval And Launch Anticipated In 2030
Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030 The Company expects XP-8121 peak net revenue potential of $1 to $3 billion Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmace...
09-09 20:34
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $9 to $12.
08-20 23:35
Xeris Biopharma Holdings Q2 EPS $(0.18) Misses $0.00 Estimate, Sales $92.100M Beat $90.225M Estimate
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $0.00 by Infinity percent. This is a 1700 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $92...
08-06 19:11
Xeris Biopharma Eliminates 2028 Convertible Notes Via Exchanges
Xeris Pharmaceuticals ( ($XERS) ) has issued an update. On July 15, 2026, Xeris...
07-18 05:26
Xeris Biopharma Announces Debt Reduction via Note Exchanges
Xeris Pharmaceuticals ( ($XERS) ) just unveiled an announcement. On June 10, 20...
06-11 19:45
Xeris Biopharma Enters Separate Exchange Agreements With Certain Holders Of Its 8.00% Convertible Senior Notes Due 2028 To Retire ~$23M Of The Notes For ~$23M In Cash And A Number Of Shares
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into separate, privately negotiated exchange agreements w...
06-11 19:09
Xeris Biopharma Holdings Raises FY2026 Sales Guidance from $375.000M-$390.000M to $380.000M-$390.000M vs $383.864M Est
Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2026 sales outlook from $375.000 million-$390.000 million to $380.000 million-$390.000 million vs $383.864 million estimate.
05-07 19:11
Xeris Biopharma Announces Board Transition as Director Retires
Xeris Pharmaceuticals ( ($XERS) ) has issued an update. On April 20, 2026, Xeri...
04-22 04:58
